• International
  • Albania
  • Bosnia and Herzegovina
  • Bulgaria
  • Croatia
  • Czech Republic
  • Estonia
  • Hungary
  • Latvia
  • Lithuania
  • Kosovo
  • North Macedonia
  • Poland
  • Romania
  • Serbia
  • Slovakia
  • Slovenia
  • Switzerland (German)
  • Switzerland (French)
  • Media
  • Meet us
  • Careers
  • Contact
ewopharma
  • Business Development
    • Licensing
    • Strategic Therapeutic Areas
    • Territory
  • Partners & Brands
    • Testimonials
  • About Ewopharma
    • Vision/Mission
    • Our Values
    • Our Strategy
    • Leadership
    • Corporate Responsibility
    • Territory
  • Media
  • Meet us
  • Careers
  • Contact
  • International
  • Albania
  • Bosnia and Herzegovina
  • Bulgaria
  • Croatia
  • Czech Republic
  • Estonia
  • Hungary
  • Latvia
  • Lithuania
  • Kosovo
  • North Macedonia
  • Poland
  • Romania
  • Serbia
  • Slovakia
  • Slovenia
  • Switzerland (German)
  • Switzerland (French)
 

Media

Our Logo

Download Logo

CONTACT

Ewopharma AG
Vordergasse 43
8200 Schaffhausen
Switzerland

Tel.: +41 52 633 09 99
E-Mail: pr@remove-this.ewopharma.com

PRESS RELEASES

  • Previous
  • 1
  • 2
  • 3
  • 4
  • Next
26.03.2020

Ewopharma and Eisai announce Commercial Partnership in Central Eastern Europe for Lenvima® (lenvatinib)

Read more
20.01.2020

Otsuka and Ewopharma join the fight against tuberculosis in Romania by launching Deltyba®

Read more
29.07.2019

Ewopharma and Vianex announce collaboration to distribute the essential antibiotic Amikacin in Switzerland

Read more
12.04.2019

Ewopharma launches new Corporate Design

Read more
06.07.2017

Shield Therapeutics and ewopharma sign Feraccru licence agreement for Switzerland

Read more
  • Previous
  • 1
  • 2
  • 3
  • 4
  • Next

Ewopharma AG
Vordergasse 43
8200 Schaffhausen
Switzerland

CONTACT

Phone: +41 52 633 09 99
E-mail:  info@remove-this.ewopharma.com

Contact for reporting side effects:

pharmacovigilance@remove-this.ewopharma.com

  • Privacy Policy
  • Cookie Policy
  • Imprint
  • VPOIS

© Copyright 2022, Ewopharma AG